ATE223387T1 - Zyklische amin derivate von substituierten chinoxalin 2.3-dione als glutamat-rezeptor- antagonisten - Google Patents

Zyklische amin derivate von substituierten chinoxalin 2.3-dione als glutamat-rezeptor- antagonisten

Info

Publication number
ATE223387T1
ATE223387T1 AT96914616T AT96914616T ATE223387T1 AT E223387 T1 ATE223387 T1 AT E223387T1 AT 96914616 T AT96914616 T AT 96914616T AT 96914616 T AT96914616 T AT 96914616T AT E223387 T1 ATE223387 T1 AT E223387T1
Authority
AT
Austria
Prior art keywords
substituted quinoxaline
dione
receptor antagonists
cyclic amine
glutamate receptor
Prior art date
Application number
AT96914616T
Other languages
English (en)
Inventor
Brian Edward Kornberg
Sham Nikam
Michael Francis Rafferty
Po-Wai Yuen
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE223387T1 publication Critical patent/ATE223387T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT96914616T 1995-06-07 1996-05-13 Zyklische amin derivate von substituierten chinoxalin 2.3-dione als glutamat-rezeptor- antagonisten ATE223387T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/474,877 US5874426A (en) 1995-06-07 1995-06-07 Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
PCT/US1996/006817 WO1996040650A1 (en) 1995-06-07 1996-05-13 Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
ATE223387T1 true ATE223387T1 (de) 2002-09-15

Family

ID=23885306

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96914616T ATE223387T1 (de) 1995-06-07 1996-05-13 Zyklische amin derivate von substituierten chinoxalin 2.3-dione als glutamat-rezeptor- antagonisten

Country Status (15)

Country Link
US (1) US5874426A (de)
EP (1) EP0830348B1 (de)
JP (1) JP3734275B2 (de)
KR (1) KR19990022482A (de)
AT (1) ATE223387T1 (de)
AU (1) AU713993B2 (de)
CA (1) CA2220076A1 (de)
DE (1) DE69623463T2 (de)
DK (1) DK0830348T3 (de)
ES (1) ES2180772T3 (de)
MX (1) MX9708563A (de)
NZ (1) NZ308317A (de)
PT (1) PT830348E (de)
WO (1) WO1996040650A1 (de)
ZA (1) ZA964763B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6191134B1 (en) 1996-06-05 2001-02-20 Warner-Lambert Company Amide derivatives of substituted quinoxaline 2, 3-diones as glutamate receptor antagonists
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US9956968B2 (en) 2014-12-19 2018-05-01 Strato, Inc. Bearing adapter side frame interface for a railway car truck

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117276A (ja) * 1991-10-23 1993-05-14 Sumitomo Pharmaceut Co Ltd 新規な3環性キノキサリンジオン誘導体
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
JPH06228112A (ja) * 1993-02-05 1994-08-16 Yamanouchi Pharmaceut Co Ltd (1h,4h)キノキサリン誘導体
TW260660B (de) * 1993-04-22 1995-10-21 Sumitomo Pharma
WO1994026747A1 (en) * 1993-05-13 1994-11-24 Neurosearch A/S Ampa antagonists and a method of treatment therewith
GB9418443D0 (en) * 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
AU5791996A (en) 1996-12-30
US5874426A (en) 1999-02-23
DK0830348T3 (da) 2003-01-06
DE69623463T2 (de) 2003-04-30
WO1996040650A1 (en) 1996-12-19
ZA964763B (en) 1997-01-08
AU713993B2 (en) 1999-12-16
JP3734275B2 (ja) 2006-01-11
CA2220076A1 (en) 1996-12-19
DE69623463D1 (de) 2002-10-10
KR19990022482A (ko) 1999-03-25
MX9708563A (es) 1997-12-31
EP0830348A1 (de) 1998-03-25
JPH11506724A (ja) 1999-06-15
NZ308317A (en) 2001-04-27
EP0830348B1 (de) 2002-09-04
ES2180772T3 (es) 2003-02-16
PT830348E (pt) 2003-01-31

Similar Documents

Publication Publication Date Title
RU94046067A (ru) Замещенные 1,2,3,4-тетрагидроизохинолины, промежуточные продукты, фармкомпозиция и способ лечения
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
EA200500536A1 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
ES2163638T3 (es) Nuevas n-(1-alquil-5-fenil-2,3,4,5-tetrahidro-1h-benzo(b)(1,5)diacepin-3-il)acetamidas.
DE69623471D1 (de) Amino-säure-derivate von substituierten chinoscalin 2,3-dion derivate als glutamat rezeptor antagonisten
EA200500173A1 (ru) Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
ATE229512T1 (de) Alkyl amin derivate von substituierte chinoscalin 2,3-dione als glutamat rezeptor antagonisten
ATE223387T1 (de) Zyklische amin derivate von substituierten chinoxalin 2.3-dione als glutamat-rezeptor- antagonisten
ATE301642T1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
CO5310533A1 (es) Derivados de amida de 2,3-dionas de quinoxalina como antago- nistas de receptor de glutamato
NO960048L (no) Difluorstaton-analoger
DE60216807D1 (de) Triazepin-derivate als neurotrope mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee